Giant Bowen’s Disease with Unilateral Verrucous Epidermal Nevus on Non-Sun-exposed Skin

Zhang Si,Cai Lin,Zhang Jianzhong,Zhou Cheng

DOI: https://doi.org/10.1684/ejd.2021.4044

2022-01-01

European Journal of Dermatology

Abstract:1 d 2 p w D ontinuous improvement of skin lesions and pruritus, with rednisone tapering to 0.5 mg/kg/d over two months. n the third patient, conventional systemic therapies were ndesirable due to underlying medical comorbidities. She iscontinued prednisone due to active gastric ulcers and oon underwent a severe relapse of skin lesions with intense tch. Besides, her laboratory tests showed positive HBsAg ith high copies of HBV. Considering all conditions, upilumab treatment was introduced. Her pruritus greatly mproved but not the skin lesions after three injections. No upilumab-attributed adverse events were observed in these hree patients. reviously, most patients with BP received the dosing regmen approved for atopic dermatitis: 600 mg SC initially, ollowed by 300 mg SC every other week [3, 4]. We folowed the same protocol here. Notably, our first and second atients were very treatment-resistant. During the most ecent relapse, these patients did not respond to treatment ith systemic corticosteroids at 0.5-0.75 mg/kg/d as an nitial control and did not even respond when we gradally increased the dosage of corticosteroids with added mmunosuppressants. Although these two patients were iniially suspected to have BP, it is very unusual for BP to be nresponsive to all aggressive therapies. Thus, we could ot completely exclude the possibility of other SABD such s BP-like EBA or anti-p200 pemphigoid, especially in the rst case who in the absence of serological tests. Neverheless, add-on dupilumab concomitant with conventional herapy in these two patients achieved rapid disease conrol with faster tapering of corticosteroids. To the best of ur knowledge, the efficacy of dupilumab for such severe nd recalcitrant conditions has only been reported twice in atients with BP [5, 6]. Our three cases suggest a potential ole of dupilumab in the treatment of refractory SABD. Furher studies with larger sample sizes are needed to confirm hese findings.